# XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

> **NCT05970302** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 52 (estimated)

## Conditions studied

- Tislelizumab
- Bevacizumab
- Oxaliplatin
- Capecitabine
- MSS/pMMR
- Metastatic Colorectal Cancer (mCRC)
- RAS-mutated
- First-Line

## Interventions

- **DRUG:** Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine

## Key facts

- **NCT ID:** NCT05970302
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-07
- **Primary completion:** 2025-07
- **Final completion:** 2026-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970302, "XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05970302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*